|
1
|
Höckel M and Vaupel P: Tumor hypoxia:
definitions and current clinical, biologic, and molecular aspects.
J Natl Cancer Inst. 93:266–276. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Carroll VA and Ashcroft M: Role of
hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the
regulation of HIF target genes in response to hypoxia, insulin-like
growth factor-I, or loss of von Hippel-Lindau function:
implications for targeting the HIF pathway. Cancer Res.
66:6264–6270. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Semenza GL, Shimoda LA and Prabhakar NR:
Regulation of gene expression by HIF-1. Novartis Found Symp.
272:33–36. 2006.
|
|
4
|
Schnitzer SE, Weigert A, Zhou J, et al:
Hypoxia enhances sphingosine kinase 2 activity and provokes
sphingosine-1-phosphate-mediated chemoresistance in A549 lung
cancer cells. Mol Cancer Res. 7:393–401. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang B, Fan L, Fang L, et al:
Hypoxia-mediated fenretinide (4-HPR) resistance in childhood acute
lymphoblastic leukemia cells. Cancer Chemother Pharmacol.
58:540–546. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Flamant L, Notte A, Ninane N, et al:
Anti-apoptotic role of HIF-1 and AP-1 in paclitaxel exposed breast
cancer cells under hypoxia. Mol Cancer. 9:1912010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sermeus A, Cosse JP, Crespin M, et al:
Hypoxia induces protection against etoposide-induced apoptosis:
molecular profiling of changes in gene expression and transcription
factor activity. Mol Cancer. 7:27–31. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang D, Weng Q, Zhang L, et al: VEGF and
Bcl-2 interact via MAPKs signaling pathway in the response to
hypoxia in neuroblastoma. Cell Mol Neurobiol. 29:391–401. 2009.
View Article : Google Scholar
|
|
9
|
Das B, Yeger H, Tsuchida R, et al: A
hypoxia-driven vascular endothelial growth factor/Flt1 autocrine
loop interacts with hypoxia-inducible factor-1alpha through
mitogen-activated protein kinase/extracellular signal-regulated
kinase 1/2 pathway in neuroblastoma. Cancer Res. 65:7267–7275.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tsuchida R, Das B, Yeger H, et al:
Cisplatin treatment increases survival and expansion of a highly
tumorigenic side-population fraction by upregulating VEGF/Flt1
autocrine signaling. Oncogene. 27:3923–3934. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee TH, Seng S, Sekine M, et al: Vascular
endothelial growth factor mediates intracrine survival in human
breast carcinoma cells through internally expressed VEGFR1/FLT1.
PLoS Med. 4:186–191. 2007. View Article : Google Scholar
|
|
12
|
Erler JT, Cawthorne CJ, Williams KJ, et
al: Hypoxia-mediated down-regulation of Bid and Bax in tumors
occurs via hypoxia-inducible factor 1-dependent and -independent
mechanisms and contributes to drug resistance. Mol Cell Biol.
24:2875–2889. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jeng KS, Sheen IS, Wang YC, et al:
Prognostic significance of preoperative circulating vascular
endothelial growth factor messenger RNA expression in resectable
hepatocellular carcinoma: a prospective study. World J
Gastroenterol. 10:643–648. 2004.PubMed/NCBI
|
|
14
|
Jinno K, Tanimizu M, Hyodo I, et al:
Circulating vascular endothelial growth factor (VEGF) is a possible
tumor marker for metastasis in human hepatocellular carcinoma. J
Gastroenterol. 33:376–382. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kwak BK, Shim HJ, Park ES, et al:
Hepatocellular carcinoma: correlation between vascular endothelial
growth factor level and degree of enhancement by multiphase
contrast-enhanced computed tomography. Invest Radiol. 36:487–492.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pang R and Poon RT: Angiogenesis and
antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett.
242:151–167. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sun W, Sohal D, Haller DG, et al: Phase 2
trial of bevacizumab, capecitabine, and oxaliplatin in treatment of
advanced hepatocellular carcinoma. Cancer. 117:3187–3192. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Thomas MB, Morris JS, Chadha R, et al:
Phase II trial of the combination of bevacizumab and erlotinib in
patients who have advanced hepatocellular carcinoma. J Clin Oncol.
27:843–850. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kaseb AO, Garrett-Mayer E, Morris JS, et
al: Efficacy of bevacizumab plus erlotinib for advanced
hepatocellular carcinoma and predictors of outcome: final results
of a phase II trial. Oncology. 82:67–74. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Smart DJ, Halicka HD, Schmuck G, et al:
Assessment of DNA double-strand breaks and gammaH2AX induced by the
topoisomerase II poisons etoposide and mitoxantrone. Mutat Res.
641:43–47. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Brady CA, Jiang D, Mello SS, et al:
Distinct p53 transcriptional programs dictate acute DNA-damage
responses and tumor suppression. Cell. 145:571–583. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Richard S, Geneviève CP, Lisa JF, et al:
hypoxia-inducible factor-1 activity associated with decreased
senescence and requires hypoxia-inducible factor-1 activity. Mol
Cancer Ther. 7:1961–1973. 2008. View Article : Google Scholar
|
|
23
|
Pommier Y, Sordet O, Antony S, et al:
Apoptosis defects and chemotherapy resistance: molecular
interaction maps and networks. Oncogene. 23:2934–2949. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jung Y, Isaacs JS, Lee S, et al:
Hypoxia-inducible factor induction by tumour necrosis factor in
normoxic cells requires receptor-interacting protein-dependent
nuclear factor kappa B activation. Biochem J. 370:1011–1017. 2003.
View Article : Google Scholar
|
|
25
|
Rius J, Guma M, Schachtrup C, et al:
NF-kappaB links innate immunity to the hypoxic response through
transcriptional regulation of HIF-1alpha. Nature. 453:807–811.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Perkins ND: Post-translational
modifications regulating the activity and function of the nuclear
factor kappa B pathway. Oncogene. 25:6717–6730. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Perkins ND and Gilmore TD: Good cop, bad
cop: the different faces of NF-kappaB. Cell Death Differ.
13:759–772. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cummins EP, Berra E, Comerford KM, et al:
Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta,
giving insight into hypoxia-induced NFkappaB activity. Proc Natl
Acad Sci USA. 103:18154–18159. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Unruh A, Ressel A, Mohamed HG, et al: The
hypoxia-inducible factor-1 alpha is a negative factor for tumor
therapy. Oncogene. 22:3213–3220. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Le QT, Denko NC and Giaccia AJ: Hypoxic
gene expression and metastasis. Cancer Metastasis Rev. 23:293–310.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sullivan R and Graham CH: Hypoxia prevents
etoposide-induced DNA damage in cancer cells through a mechanism
involving hypoxia-inducible factor 1. Mol Cancer Ther. 8:1702–1713.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rohwer N, Dame C, Haugstetter A, et al:
Hypoxia-inducible factor 1alpha determines gastric cancer
chemosensitivity via modulation of p53 and NF-kappaB. PLoS One.
5:120382010. View Article : Google Scholar
|
|
33
|
Ferrara N: Vascular endothelial growth
factor: basic science and clinical progress. Endocrine Rev.
25:581–611. 2004. View Article : Google Scholar
|
|
34
|
Pal S, Datta K and Mukhopadhyay D: Central
role of p53 on regulation of vascular permeability factor/vascular
endothelial growth factor (VPF/VEGF) expression in mammary
carcinoma. Cancer Res. 61:6952–6957. 2001.PubMed/NCBI
|
|
35
|
Ravi R, Mookerjee B, Bhujwalla ZM, et al:
Regulation of tumor angiogenesis by p53-induced degradation of
hypoxia-inducible factor 1alpha. Genes Dev. 14:34–44.
2000.PubMed/NCBI
|
|
36
|
Yang J, Ahmed A, Poon E, et al:
Small-molecule activation of p53 blocks hypoxia-inducible factor
1alpha and vascular endothelial growth factor expression in vivo
and leads to tumor cell apoptosis in normoxia and hypoxia. Mol Cell
Biol. 29:2243–2253. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Walmsley SR, Print C, Farahi N, et al:
Hypoxia-induced neutrophil survival is mediated by
HIF-1alpha-dependent NF-kappaB activity. J Exp Med. 201:105–115.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang CY, Cusack JC, Liu R, et al: Control
of inducible chemoresistance: enhanced anti-tumor therapy through
increased apoptosis by inhibition of NF-κB. Nat Med. 5:412–417.
1999. View Article : Google Scholar : PubMed/NCBI
|
